Vera Therapeutics reports Q2 results on August 13 with the stock under real pressure — down 25% over the past month and trading at $31.58, against a bull consensus that sees fair value more than twice as high.
The most striking signal into the print is options positioning. Put demand has surged to its most defensive level in months: the put/call ratio hit 0.63, more than two standard deviations above its 20-day average of 0.40. That z-score of 2.05 is close to the highest defensive reading of the past year, with the 52-week peak at 0.96. The shift is sharp — through all of July the PCR held in a tight band around 0.35, then jumped abruptly in the first week of August as the stock sold off hard. Options traders are paying materially more attention to downside protection than at any point in recent memory.
Short interest reinforces the skeptical posture. Bears hold 23.4% of the free float short — a level flagged as "high" — and that position has grown roughly 26% over the past month, reflecting a meaningful build in bearish conviction after the stock peaked earlier in the summer. The ORTEX short score sits at 63.6, elevated but easing slightly from 65.4 at the start of August. The borrow market, however, offers no near-term squeeze catalyst: availability runs at 716%, meaning there are more than seven shares available to lend for every one already borrowed, and the cost to borrow remains negligible at 0.61% — albeit rising, up 24% on the week and 36% over the month. Positioning is heavily short, but the structural conditions for a violent squeeze are not there.
The bull-versus-bear debate centres entirely on the commercial launch of atacicept (Trutakna), which received FDA approval for IgA nephropathy. Analysts are broadly constructive: twelve carry Buy ratings, and a cluster of firms — including B of A Securities and Guggenheim — raised targets in early July, with the Street mean near $82. Bears, however, point to a crowded market where Otsuka's Voyxact and Asahi Kasei's Filspari are already entrenched, and a list price of roughly $425,000 annually that faces real payer pushback. The stock's 40% year-to-date decline despite the approval shows the market is not yet persuaded the launch will deliver. Peers have traded better: VKTX gained nearly 8% on the week and SRRK rose 12%, while VERA slipped 2% — a divergence that underscores how much stock-specific launch risk is being priced in.
The CEO, Marshall Fordyce, sold roughly $2 million of stock in early July at prices well above where the stock now trades, adding another layer of complexity to the narrative heading in.
The August 13 print will test whether early Trutakna prescribing data and revenue guidance can close the gap between a $31 stock and an $82 analyst consensus — or confirm the market's fear that commercial uptake is slower than the bull case requires.
See the live data behind this article on ORTEX.
Open VERA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
